Follow the people · Insider
Neil Harris Cohen
Neil Harris Cohen files insider transactions with the SEC as a director of Chemomab Therapeutics (CMMB). We hold 2 disclosed purchases and sales filed since 11 March 2021, 2 of them in the last 90 days.
- Files forCMMB
- Disclosed buys and sells2 in all, 2 in the last 90 days
- Last disclosure1 September 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 16 July 2020 — 28 August 2026Director · Chemomab Therapeutics (CMMB)32 Form 4 lines · source: SEC Form 4
- Filed 16 July 2020 — 16 July 2020interim CEO · Anchiano Therapeutics (ANCN)1 Form 4 line · source: SEC Form 4
Everything they disclosed
33 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 1,304 shares of Chemomab TherapeuticsSEC Form 41 September 2026American Depositary Shares · traded 27 August 2026 · filed 1 September 2026
- ▼ sold on the open market 1,000 shares of Chemomab TherapeuticsSEC Form 41 September 2026American Depositary Shares · traded 28 August 2026 · filed 1 September 2026
- was granted 172 shares of Chemomab Therapeutics (a derivative holding)SEC Form 41 September 2026Stock option (right to buy American Depositary Shares) · traded 16 July 2020 · filed 1 September 2026
- was granted 2,971 shares of Chemomab Therapeutics (a derivative holding)SEC Form 41 September 2026Stock option (right to buy American Depositary Shares) · traded 19 April 2021 · filed 1 September 2026
- was granted 1,705 shares of Chemomab Therapeutics (a derivative holding)SEC Form 41 September 2026Stock option (right to buy American Depositary Shares) · traded 7 March 2022 · filed 1 September 2026
- was granted 1,714 shares of Chemomab Therapeutics (a derivative holding)SEC Form 41 September 2026Stock option (right to buy American Depositary Shares) · traded 21 March 2023 · filed 1 September 2026
- was granted 2,520 shares of Chemomab Therapeutics (a derivative holding)SEC Form 41 September 2026Stock option (right to buy American Depositary Shares) · traded 18 March 2024 · filed 1 September 2026
- was granted 3,821 shares of Chemomab Therapeutics (a derivative holding)SEC Form 41 September 2026Stock option (right to buy American Depositary Shares) · traded 16 March 2025 · filed 1 September 2026
- was granted 5,172 shares of Chemomab Therapeutics (a derivative holding)SEC Form 41 September 2026Stock option (right to buy American Depositary Shares) · traded 16 March 2026 · filed 1 September 2026
- was granted 6,875 shares of Chemomab Therapeutics (a derivative holding)SEC Form 423 March 2023Option to Purchase American Depositary Shares · traded 16 March 2023 · filed 23 March 2023
- was granted 6,820 shares of Chemomab Therapeutics (a derivative holding)SEC Form 423 March 2023Option to Purchase American Depositary Shares · traded 7 March 2022 · filed 23 March 2023
- was granted 11,884 shares of Chemomab Therapeutics (a derivative holding)SEC Form 423 March 2023Option to Purchase American Depositary Shares · traded 19 April 2021 · filed 23 March 2023
- was granted 688 shares of Chemomab Therapeutics (a derivative holding)SEC Form 423 March 2023Option to Purchase American Depositary Shares · traded 16 March 2021 · filed 23 March 2023
- was granted 6,820 shares of Chemomab Therapeutics (a derivative holding)SEC Form 418 November 2022Option to Purchase American Depositary Shares · traded 7 March 2022 · filed 18 November 2022
- was granted 11,884 shares of Chemomab Therapeutics (a derivative holding)SEC Form 418 November 2022Option to Purchase American Depositary Shares · traded 19 April 2021 · filed 18 November 2022
- was granted 688 shares of Chemomab Therapeutics (a derivative holding)SEC Form 418 November 2022Option to Purchase American Depositary Shares · traded 16 March 2021 · filed 18 November 2022
- ▼ sold on the open market 2,409 shares of Chemomab TherapeuticsSEC Form 418 November 2022American Depositary Shares · traded 16 November 2022 · filed 18 November 2022
- was granted 6,820 shares of Chemomab Therapeutics (a derivative holding)SEC Form 419 May 2022Option to Purchase American Depositary Shares · traded 7 March 2022 · filed 19 May 2022
- was granted 11,884 shares of Chemomab Therapeutics (a derivative holding)SEC Form 419 May 2022Option to Purchase American Depositary Shares · traded 19 April 2021 · filed 19 May 2022
- was granted 688 shares of Chemomab Therapeutics (a derivative holding)SEC Form 419 May 2022Option to Purchase American Depositary Shares · traded 16 March 2021 · filed 19 May 2022
- ▲ bought on the open market 2,000 shares of Chemomab TherapeuticsSEC Form 419 May 2022American Depositary Shares · traded 18 May 2022 · filed 19 May 2022
- was granted 6,820 shares of Chemomab Therapeutics (a derivative holding)SEC Form 415 March 2022Option to Purchase American Depositary Shares · traded 7 March 2022 · filed 15 March 2022
- was granted 11,884 shares of Chemomab Therapeutics (a derivative holding)SEC Form 415 March 2022Option to Purchase American Depositary Shares · traded 19 April 2021 · filed 15 March 2022
- was granted 688 shares of Chemomab Therapeutics (a derivative holding)SEC Form 415 March 2022Option to Purchase American Depositary Shares · traded 16 March 2021 · filed 15 March 2022
- ▲ bought on the open market 2,000 shares of Chemomab TherapeuticsSEC Form 415 March 2022American Depositary Shares · traded 14 March 2022 · filed 15 March 2022
- ▲ bought on the open market 2,000 shares of Chemomab TherapeuticsSEC Form 415 March 2022American Depositary Shares · traded 14 March 2022 · filed 15 March 2022
- ▲ bought on the open market 2,000 shares of Chemomab TherapeuticsSEC Form 415 March 2022American Depositary Shares · traded 14 March 2022 · filed 15 March 2022
- was granted 6,820 shares of Chemomab Therapeutics (a derivative holding)SEC Form 49 March 2022Option to Purchase American Depositary Shares · traded 7 March 2022 · filed 9 March 2022
- ▲ bought on the open market 2,000 shares of Chemomab TherapeuticsSEC Form 48 December 2021American Depositary Shares · traded 6 December 2021 · filed 8 December 2021
- was granted 11,884 shares of Chemomab Therapeutics (a derivative holding)SEC Form 421 April 2021Option to Purchase American Depositary Shares · traded 19 April 2021 · filed 21 April 2021
- ▲ bought on the open market 2,409 shares of Chemomab TherapeuticsSEC Form 426 March 2021American Depositary Shares · traded 16 March 2021 · filed 26 March 2021
- ▲ bought on the open market 688 shares of Chemomab Therapeutics (a derivative holding)SEC Form 426 March 2021Option to Purchase American Depositary Shares · traded 16 March 2021 · filed 26 March 2021
- was granted 55,000 shares of Anchiano Therapeutics (a derivative holding)SEC Form 411 March 2021Stock Option (right to buy) · traded 16 July 2020 · filed 11 March 2021
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.